Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014–2016

Objective Knowledge regarding the prevalence and distribution of human papillomavirus (HPV) genotyping in healthy women is important in establishing strategies for cervical cancer screening and HPV vaccination. Methods A total of 18,170 women who visited a Korean Medical Institute for health check-ups were recruited retrospectively; they underwent HPV genotyping and conventional cervical cytology. An HPV DNA test was performed using the Anyplex™ II HPV 28 detection system (Seegene) or HPV Liquid Bead Microarray (Osang Healthcare). The distribution of HPV genotypes was assessed according to cervical cytology and age. Results HPV was detected in 3,037 (16.71%) of the 18,170 women enrolled, and 2,268 (12.48%) were positive for high-risk (HR) HPV. In total, HPV 53 (9.69% of all detected HPV viruses) was the most common type; HPV 58 (7.90%) and 52 (7.81%) were also common. HPV 54 (6.99%) was common in low-risk subjects. Overall and in the normal cytology group, the most common HPV genotype was HPV 53, whereas HPV 58 was more common in women who had atypical squamous cells of undetermined significance or low-grade squamous intraepithelial neoplasia cervical cytology. In addition, HPV 16 was the most common type in cases with high-grade squamous intraepithelial neoplasia (HSIL)/atypical squamous cells-cannot exclude HSIL. Among women with normal cytology, 76 of 231 (32.9%) women under 24 years of age were positive for HR HPV, whereas 84 of 852 (9.9%) women aged 55–59 years were positive. Conclusion HPV 53 was the most prevalent genotype in healthy women. Distribution of HPV genotypes varied with cervical cytology and age. Our study provides important baseline data for the recently implemented national HPV vaccination program.

[1]  M. Plummer,et al.  Worldwide burden of cancer attributable to HPV by site, country and HPV type , 2017, International journal of cancer.

[2]  Hongbing Shen,et al.  Independent prognostic role of human papillomavirus genotype in cervical cancer , 2017, BMC Infectious Diseases.

[3]  Jane J. Kim,et al.  Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua , 2017, BMJ Open.

[4]  G. Krashias,et al.  HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities , 2017, BMC Infectious Diseases.

[5]  W. Termrungruanglert,et al.  A Model Approach for Assessing the Benefits of HPV Testing against Cytology in Screening for Cervical Cancer Precursors in Thailand , 2017, Asian Pacific journal of cancer prevention : APJCP.

[6]  K. Jung,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014 , 2017, Cancer research and treatment : official journal of Korean Cancer Association.

[7]  Jae Kwan Lee,et al.  Human Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea , 2016, Journal of cancer prevention.

[8]  Kyu-Won Jung,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013 , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[9]  J. Cuzick Gardasil 9 joins the fight against cervix cancer , 2015, Expert review of vaccines.

[10]  C. Cho,et al.  The Korean guideline for cervical cancer screening , 2015, Journal of gynecologic oncology.

[11]  M. Karlsson,et al.  Evaluation of HPV Genotyping Assays for Archival Clinical Samples. , 2015, The Journal of molecular diagnostics : JMD.

[12]  J. Cuzick,et al.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.

[13]  E. J. Mayeaux,et al.  Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. , 2015, Gynecologic oncology.

[14]  S. Rosini,et al.  Clinical Interventions in Aging Dovepress , 2022 .

[15]  M. Kwon,et al.  Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  T. Iftner,et al.  Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? , 2014, Cancer Causes & Control.

[17]  R. Sahli,et al.  Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV Assay for Human Papillomavirus Genotyping , 2013, Journal of Clinical Microbiology.

[18]  J. Monsonego,et al.  Prévalence des génotypes d’HPV chez les femmes en France : implications pour le dépistage et la vaccination , 2013 .

[19]  Sunmie Kim,et al.  Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women , 2013, Obstetrics & gynecology science.

[20]  M. Plummer,et al.  Global burden of human papillomavirus and related diseases. , 2012, Vaccine.

[21]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[22]  Sung Soon Kim,et al.  Prevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development , 2010, Virology Journal.

[23]  E. Armstrong,et al.  Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types , 2010, Journal of managed care pharmacy : JMCP.

[24]  Joakim Dillner,et al.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.

[25]  S. Hur,et al.  Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. , 2008, Journal of microbiology and biotechnology.

[26]  T. Hwang,et al.  Clinical Efficacy of Human Papillomavirus DNA Detection in Urine from Patients with Various Cervical Lesions , 2007, Journal of Korean medical science.

[27]  J. Nam,et al.  Human papillomavirus genotyping using HPV DNA chip analysis in Korean women , 2006, International Journal of Gynecologic Cancer.

[28]  S. Franceschi,et al.  Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[29]  S. Franceschi,et al.  Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. , 2004, The Journal of infectious diseases.

[30]  U. Liebert,et al.  PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[31]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[32]  K. Syrjänen,et al.  [Prevalence of genotype-specific HPV infection among women in France: implications for screening and vaccination]. , 2013, Gynécologie Obstétrique & Fertilité.

[33]  Leslie Carol Botha Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial , 2010 .

[34]  F. X. Bosch,et al.  Type-specific human papillomavirus distribution in invasive cervical cancer in Korea, 1958-2004. , 2010, Asian Pacific journal of cancer prevention : APJCP.